Medicus Pharma Acquires Antev to Advance Teverelix for Prostate Cancer and AUR

Medicus Pharma Ltd. announced the successful acquisition of 98.6% of UK-based Antev Limited, a clinical-stage biotech company, for a total consideration of approximately US$2.97 million in cash and 1.6 million common shares of Medicus. The acquisition follows a securities exchange agreement signed in June 2025. Former Antev shareholders are also eligible for up to US$65 million in milestone-based contingent payments, tied to potential FDA Phase 2 and New Drug Application approvals.

Antev specializes in developing Teverelix, a next-generation GnRH antagonist targeting patients with cardiovascular high-risk prostate cancer and those experiencing acute urinary retention (AUR) due to an enlarged prostate. This acquisition strengthens Medicus’s clinical development pipeline by adding a potentially first-in-market therapy addressing a significant unmet medical need.

“We are delighted to complete the acquisition of Antev, which not only adds strategic depth to our drug development pipeline but also strengthens our team, both at the board and management levels. We believe, Teverelix, a next-generation GnRH antagonist, is well-positioned to become a first-in-class product to prevent acute urinary retention relapse due to enlarged prostate, and to treat advanced prostate cancer in patients with high cardiovascular risk profile, collectively representing approximately US$6 billion in potential market opportunity,” stated Dr. Raza Bokhari, Medicus’s Executive Chairman & CEO 

Following the acquisition, Medicus has expanded its leadership team. Patrick J. Mahaffy, former chairman of Antev and ex-CEO of Clovis Oncology and Pharmion Corporation, has been appointed to Medicus’s Board of Directors. Additionally, Dr. Paul Marchetto and Dr. Faisal Mehmud will co-chair Antev’s board, with Carolyn Bonner and Viktoria Slepeniuk also joining. Amit Kohli will continue as Interim CEO of Antev, while the issued shares will remain under lock-up and voting agreements for 36 months to ensure alignment with Medicus management.